Login to Your Account

Gilead's Hepsera Approved To Treat Chronic Hepatitis B

By Randall Osborne

Tuesday, September 24, 2002
Less than two months after an advisory panel unanimously recommended approval of Gilead Sciences Inc.'s Hepsera (adefovir dipivoxil) for chronic hepatitis B, the FDA has given its expected nod and the company plans to ship the drug this week - with a price tag that was higher than some analysts had forecast.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription